<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152358</url>
  </required_header>
  <id_info>
    <org_study_id>20126003312-30</org_study_id>
    <secondary_id>2012-003312-30</secondary_id>
    <nct_id>NCT02152358</nct_id>
  </id_info>
  <brief_title>PTH - Preemptive Treatment for Herpesviridae</brief_title>
  <acronym>PTH</acronym>
  <official_title>Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to show that a preemptive treatment by ganciclovir (for positive CMV
      viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the number of
      ventilator-free days at Day 60.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days at Day 60</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day 60 mortality</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation in survivors</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ventilator-associated pneumonia</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bacteremia</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>days 3, 5, 7, 14, 21 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure related to aciclovir or its placebo</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucopenia related to ganciclovir or its placebo</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to oropharyngeal negativation of HSV PCR</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to blood negativation of CMV PCR</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of herpetic bronchopneumonia</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of active CMV infection</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Viral Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with a positive CMV PCR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganciclovir placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with a positive CMV PCR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with a PCR positive for HSV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aciclovir placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with a positive PCR for HSV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aciclovir</intervention_name>
    <description>Intravenous 15 mg/kg/d during 14 days</description>
    <arm_group_label>Aciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
    <description>intravenous 10 mg/kg/d for 14 days</description>
    <arm_group_label>Ganciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Ganciclovir placebo</arm_group_label>
    <arm_group_label>Aciclovir placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mechanical ventilation &gt; 96 hrs and expected duration of mechanical ventilation of at
             least 2 days

          -  positive blood CMV PCR (500 IU/ml) OR positive oropharyngeal HSV PCR

          -  age &gt; 18 years

          -  informed consent

          -  negative pregnancy test

        Exclusion Criteria:

          -  &lt; 18 years

          -  Receiving ganciclovir or aciclovir or another antiviral agent active against HSV/CMV

          -  Had received antiviral agent active against HSV/CMV during the previous month

          -  Hypersensitivity to aciclovir/ganciclovir

          -  Pregnancy

          -  Breast feeding

          -  Bone marrow failure

          -  Solid organ recipients

          -  Bone marrow recipients

          -  HIV positive patients

          -  Receiving immunosuppressive agents

          -  SAPS II &gt; 75

          -  Withdrawing/withholding

          -  Neutropenia (&lt; 500 mm3)

          -  Thrombocytopenia (&lt; 25 G/L)

          -  ICU readmission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Papazian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHM - AMU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Papazian, MD, PhD</last_name>
    <phone>+33491965836</phone>
    <email>laurent.papazian@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Charles Reynier, MD</last_name>
    <phone>+33491382747</phone>
    <email>jean-charles.reynier@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Papazian, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Papazian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Herpes simplex virus</keyword>
  <keyword>ICU</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>mortality</keyword>
  <keyword>ventilator-free days</keyword>
  <keyword>PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

